CA
NZ
UK
AU
IND
US
●Phase 3 trial underway:PDS Biotechnology is running the VERSATILE-003 trial evaluating its Versamune HPV immunotherapy in HPV16-positive head and neck cancer.
●Positive extension data:Reviva reported a full dataset from a one-year Phase 3 RECOVER open-label extension study evaluating brilaroxazine in schizophrenia.
Skye Bioscience (NASDAQ:SKYE) is positioning itself for a bigger role in the crowded obesity-drug arena, and a mid-August 2026 transaction has given the effort freshCapitaland a new strategic dimension. The clinical-stage company, whose lead program targets a novel mechanism for weight management, announced a …
● The company's losses deepened as it invested in commercialization.
●New patent:On August 5, 2026, Vivos announced U.S.PatentNo. 12,697,190, broadening protection for its Vivos CARE oral medical-device technology.
GeoVax Labs (NASDAQ:GOVX) is advancing an ambitious vaccine and immunotherapy pipeline against a backdrop of tight finances. The company is pushing forward with late-stage plans for a smallpox and mpox vaccine while flagging the funding challenges that shadow many small biotechs.
Kairos Pharma (NYSE:KAPA) is a small oncology company assembling a body of clinical evidence for a novel antibody, and a series of positive interim readouts has begun to build a case that the stock deserves a fresh look. The company's lead candidate targets a …
● The company described a rebound in revenue and maintained its guidance.
Nano-X Imaging (NASDAQ:NNOX) is pursuing an ambitious vision to make medical imaging more accessible through novel X-ray technology and AI, and recent commercial deals suggest the company is quietly building momentum. After years of development and skepticism, Nano-X has been signing multi-year deployment agreements …
●Delisting determination:On August 19, 2026, OSR Health disclosed it had received aNasdaqStaff Delisting Determination for failing to maintain the $1.00 minimum bid price.
Please wait processing your request...